摘要
目的探讨气滞胃痛颗粒对幽门螺旋杆菌(HP)阴性慢性胃炎患者的临床疗效。方法 141例HP阴性慢性胃炎患者随机分为气滞胃痛颗粒组106例和奥美拉唑肠溶胶囊组35例,用药4周,以总有效率、显效率和症状评价评估疗效并观察不良反应。结果气滞胃痛颗粒组和奥美拉唑肠溶胶囊组患者治疗4周的总有效率分别为92.39%和82.35%,组间差异无统计学意义;不良反应发生率分别为10.4%和8.6%,组间差异无统计学意义。然而,显效率(55.77%对29.41%)组间差异显著(P=0.008)。结论气滞胃痛颗粒治疗HP阴性慢性胃炎疗效与奥美拉唑肠溶胶囊相近或更优,安全性类似,有待进一步评价。
Objective To study the effect of Qizhi Weitong granules on chronic gastritis patients without H.pylori （HP） infection. Methods Patients without HP infection were randomly divided into Qizhi Weitong granules group （n=106） and omeprazole oral enteric-coated capsules group （n=35）. Therapeutic effectiveness was evaluated by total effective rate, excellence rate and symptomatic evaluation after treatment of 4 weeks. Adverse reaction was observed during the treatment. Results The effective rate of the patients after 4 weeks in Qizhi Weitong granules group and omeprazole oral enteric-coated capsules group were 92.39% and 82.35%, and the adverse reaction rates were 10.4% and 8.6% respectively. But the excellence rates were 55.77% and 29.41% （P=0.008）. Conclusion Qizhi Weitong granules has a similar or better therapeutic efficacy compared with omeprazole oral enteric-coated capsule in treatment of chronic gastritis patients without HP infection.
出处
《世界临床药物》
CAS
2013年第2期97-100,共4页
World Clinical Drug
